scispace - formally typeset
J

Jian Cao

Researcher at Rutgers University

Publications -  33
Citations -  2219

Jian Cao is an academic researcher from Rutgers University. The author has contributed to research in topics: Epigenetics & Cancer. The author has an hindex of 18, co-authored 33 publications receiving 1661 citations. Previous affiliations of Jian Cao include Chinese Academy of Sciences & Laboratory of Molecular Biology.

Papers
More filters
Journal ArticleDOI

The Cholesterol Absorption Inhibitor Ezetimibe Acts by Blocking the Sterol-Induced Internalization of NPC1L1

TL;DR: A model wherein cholesterol is internalized into cells with NPC1L1 through clathrin/AP2-mediated endocytosis and ezetimibe inhibits cholesterol absorption by blocking the internalization of NPC1 L1 is suggested.
Journal ArticleDOI

Histone Ubiquitination and Deubiquitination in Transcription, DNA Damage Response, and Cancer

TL;DR: This review will summarize the current understanding of histone ubiquitination and deubiquitination, and focus on how they are regulated by hist one ubiquitin ligases and deUBiquitinating enzymes.
Journal ArticleDOI

An easy and efficient inducible CRISPR/Cas9 platform with improved specificity for multiple gene targeting

TL;DR: By combining the inducible and multiplex genome editing approaches, this team was able to simultaneously delete Lysine Demethylase 5A, 5B and 5C efficiently in vitro and in vivo.
Journal ArticleDOI

Immune suppressive landscape in the human esophageal squamous cell carcinoma microenvironment.

TL;DR: A detailed immune cell atlas of esophageal squamous cell carcinoma at single-cell resolution is obtained and indicates several immunosuppressive mechanisms that may be simultaneously responsible for the failure of immuno-surveillance.
Journal ArticleDOI

Epigenetic Regulation by Lysine Demethylase 5 (KDM5) Enzymes in Cancer

TL;DR: Preclinical studies suggest inhibition of the KDM5/JARID1 family of histone demethylases can suppress tumorigenesis and provide strong rationale for development of their inhibitors for use in cancer therapy.